Reply to Decroo et al.: High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis

Detalles Bibliográficos
Autores principales: Dooley, Kelly E., Miyahara, Sachiko, von Groote-Bidlingmaier, Florian, Sun, Xin, Hafner, Richard, Rosenkranz, Susan L., Ignatius, Elisa H., Nuermberger, Eric L., Moran, Laura, Donahue, Kathleen, Swindells, Susan, Vanker, Naadira, Diacon, Andreas H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Thoracic Society 2020
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301745/
https://www.ncbi.nlm.nih.gov/pubmed/32130866
http://dx.doi.org/10.1164/rccm.202002-0359LE
_version_ 1783547749685264384
author Dooley, Kelly E.
Miyahara, Sachiko
von Groote-Bidlingmaier, Florian
Sun, Xin
Hafner, Richard
Rosenkranz, Susan L.
Ignatius, Elisa H.
Nuermberger, Eric L.
Moran, Laura
Donahue, Kathleen
Swindells, Susan
Vanker, Naadira
Diacon, Andreas H.
author_facet Dooley, Kelly E.
Miyahara, Sachiko
von Groote-Bidlingmaier, Florian
Sun, Xin
Hafner, Richard
Rosenkranz, Susan L.
Ignatius, Elisa H.
Nuermberger, Eric L.
Moran, Laura
Donahue, Kathleen
Swindells, Susan
Vanker, Naadira
Diacon, Andreas H.
author_sort Dooley, Kelly E.
collection PubMed
description
format Online
Article
Text
id pubmed-7301745
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Thoracic Society
record_format MEDLINE/PubMed
spelling pubmed-73017452020-06-18 Reply to Decroo et al.: High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis Dooley, Kelly E. Miyahara, Sachiko von Groote-Bidlingmaier, Florian Sun, Xin Hafner, Richard Rosenkranz, Susan L. Ignatius, Elisa H. Nuermberger, Eric L. Moran, Laura Donahue, Kathleen Swindells, Susan Vanker, Naadira Diacon, Andreas H. Am J Respir Crit Care Med Correspondence American Thoracic Society 2020-06-15 2020-06-15 /pmc/articles/PMC7301745/ /pubmed/32130866 http://dx.doi.org/10.1164/rccm.202002-0359LE Text en Copyright © 2020 by the American Thoracic Society https://creativecommons.org/licenses/by-nc-nd/4.0/This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ). For commercial usage and reprints, please contact Diane Gern (dgern@thoracic.org).
spellingShingle Correspondence
Dooley, Kelly E.
Miyahara, Sachiko
von Groote-Bidlingmaier, Florian
Sun, Xin
Hafner, Richard
Rosenkranz, Susan L.
Ignatius, Elisa H.
Nuermberger, Eric L.
Moran, Laura
Donahue, Kathleen
Swindells, Susan
Vanker, Naadira
Diacon, Andreas H.
Reply to Decroo et al.: High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis
title Reply to Decroo et al.: High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis
title_full Reply to Decroo et al.: High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis
title_fullStr Reply to Decroo et al.: High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis
title_full_unstemmed Reply to Decroo et al.: High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis
title_short Reply to Decroo et al.: High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis
title_sort reply to decroo et al.: high-dose first-line treatment regimen for recurrent rifampicin-susceptible tuberculosis
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301745/
https://www.ncbi.nlm.nih.gov/pubmed/32130866
http://dx.doi.org/10.1164/rccm.202002-0359LE
work_keys_str_mv AT dooleykellye replytodecrooetalhighdosefirstlinetreatmentregimenforrecurrentrifampicinsusceptibletuberculosis
AT miyaharasachiko replytodecrooetalhighdosefirstlinetreatmentregimenforrecurrentrifampicinsusceptibletuberculosis
AT vongrootebidlingmaierflorian replytodecrooetalhighdosefirstlinetreatmentregimenforrecurrentrifampicinsusceptibletuberculosis
AT sunxin replytodecrooetalhighdosefirstlinetreatmentregimenforrecurrentrifampicinsusceptibletuberculosis
AT hafnerrichard replytodecrooetalhighdosefirstlinetreatmentregimenforrecurrentrifampicinsusceptibletuberculosis
AT rosenkranzsusanl replytodecrooetalhighdosefirstlinetreatmentregimenforrecurrentrifampicinsusceptibletuberculosis
AT ignatiuselisah replytodecrooetalhighdosefirstlinetreatmentregimenforrecurrentrifampicinsusceptibletuberculosis
AT nuermbergerericl replytodecrooetalhighdosefirstlinetreatmentregimenforrecurrentrifampicinsusceptibletuberculosis
AT moranlaura replytodecrooetalhighdosefirstlinetreatmentregimenforrecurrentrifampicinsusceptibletuberculosis
AT donahuekathleen replytodecrooetalhighdosefirstlinetreatmentregimenforrecurrentrifampicinsusceptibletuberculosis
AT swindellssusan replytodecrooetalhighdosefirstlinetreatmentregimenforrecurrentrifampicinsusceptibletuberculosis
AT vankernaadira replytodecrooetalhighdosefirstlinetreatmentregimenforrecurrentrifampicinsusceptibletuberculosis
AT diaconandreash replytodecrooetalhighdosefirstlinetreatmentregimenforrecurrentrifampicinsusceptibletuberculosis

Ejemplares similares